immo!nvest – Die Plattform für Standorte und Immobilien

Tag: Medizintechnik

  • Investments strengthen production capacities in the medical technology sector

    Investments strengthen production capacities in the medical technology sector

    The Burgdorf-based medtech company Ypsomed has invested 25 million Swiss francs in the remodelling and construction of a new machine tool park in Solothurn. In order to meet the growing global demand for injection systems and offer customers the highest quality, Ypsomed intends to significantly expand its position and capacity in the production of injection moulds, according to a press release. At the Solothurn site, the company intends to concentrate on the design and manufacture of plastic injection moulds for pens and autoinjectors.

    The commissioning of the mould construction facility marks the start of the implementation of a 200 million Swiss franc investment package to develop the site. Two new high-volume assembly systems with associated injection moulding systems for autoinjectors are to be opened in the coming months. The company has also announced plans to build a fully automated high-bay warehouse at the Solothurn site by the end of 2027. At the same time, a conference centre (Ypsomed Forum) is to be built there with space for around 300 guests. “The investment in the new toolmaking facility in Solothurn is a clear commitment to the development of our sites in Switzerland,” said Simon Michel, CEO of Ypsomed.

    The company also wants to continue to grow internationally in order to consolidate its position in the medical technology market and meet the increasing demand for injection systems for self-medication. in 2025, Ypsomed opened its first own plant in Changzhou, China, and started the expansion of its production site in Schwerin, Germany. A new site is currently under construction in Holly Springs in the US state of North Carolina.

    The investment also serves to double the number of staff in this area. The current number of 35 employees plus trainees is set to grow to 100 employees and apprentices.

  • Life Sciences Campus Allschwil continues to grow

    Life Sciences Campus Allschwil continues to grow

    With the official laying of the foundation stone for the ALL laboratory building in Allschwil, the Switzerland Innovation Park Basel Area marks a new stage in the development of a world-leading life sciences location. Domenico Scala, President of the Innovation Park, Stephen Wilson, CEO of BIIE, and Johannes Eisenhut, Managing Director of Senn Development AG, celebrated the start of construction with a time capsule in which representatives of the regional economy, politics and schoolchildren from the Swiss International School recorded their wishes for the future.

    Research building with a focus on sustainability
    The new ALL building is scheduled for completion in 2027 and will offer around 21,500 square metres of state-of-the-art laboratory and office space in accordance with the SNBS Platinum sustainability standard. This third collaboration between Senn and the architecture firm Herzog & de Meuron on the Innovation Park’s Main Campus strengthens the long-term orientation of the site. The investor Senn is aiming to intensively promote collaboration across the entire campus in order to maximise the innovative strength of researchers and companies.

    Research for tomorrow’s health
    With the BIIE, the ALL building will be home to one of the most significant investments in the life sciences sector. The BIIE, supported by 15 years of funding totalling USD 1 billion from the Basel Botnar Foundation, is dedicated to researching the immune system in order to develop new solutions for the diagnosis, treatment and prevention of diseases in children and adolescents worldwide. “The choice of location was crucial for our institute. The Main Campus offers exactly the right environment to meet our high standards,” explains Stephen Wilson.

    A strong life sciences cluster in Europe
    As part of the national innovation park Switzerland Innovation, the Switzerland Innovation Park Basel Area is an important hub for research and development in Switzerland. With sites in Allschwil, Jura and the Novartis Campus in Basel, the park focuses on the key areas of biotechnology, medical technology, digital health and industrial transformation. Around 1,200 specialists from 92 companies and 12 research groups work at the Basel site, making it the largest area for life sciences in a Swiss innovation park.

    Future prospects for Allschwil and Switzerland
    The construction of the laboratory building symbolises the sustainable development of Basel as a life sciences location and the innovative strength of the region. “We are using the knowledge gained from previous projects such as the HQ main building and HORTUS and are continuing to focus on sustainable infrastructure and the promotion of synergies,” emphasises Johannes Eisenhut. The development of the Switzerland Innovation Park Basel Area shows how Basel is becoming an international centre for life science research and technology – a win-win situation for science, business and society.

  • Baden Cantonal Hospital focusses on local companies and sustainability

    Baden Cantonal Hospital focusses on local companies and sustainability

    Baden Cantonal Hospital (KSB) has carried out around 250 publicly tendered procurements over the course of the six-year construction phase of the new building. According to a press release, these tenders resulted in a total of 1066 contracts for work and services. The most recent tender was for the furniture. According to the KSB, the new hospital building lives up to the Swiss made label. 97 per cent of the 177 companies involved in the new building come from Switzerland. Only 3 per cent of the contracts were awarded to companies in Germany and Italy.

    A total of 25 per cent of the companies involved in the construction are based in the canton of Aargau and 40 per cent in the canton of Zurich. “We are proud that KSB has thus made a significant contribution to local and regional value creation,” KSB CEO Adrian Schmitter is quoted as saying.

    Thanks to the high presence of local companies, KSB has also set an example in terms of sustainability, Schmitter continues. “During the construction phase, it was above all a project of short distances for the trade companies involved. This resulted in various synergy effects,” says the CEO. This also applies to the time after commissioning, when reworking, maintenance or similar may be required.

    With a usable area of 76,215 square metres, the new building will offer around 30 percent more space than the building in which KSB has been housed since 1978. Commissioning is scheduled for the end of February 2025.

    The move should then be completed within five days. A total of 4571 cubic metres of medical technology and other goods will be moved, according to a KSB press release. This corresponds to the load of 76 lorries of 40 tonnes each.

  • New GLC research building, ETH Zurich: Today's facade technology for tomorrow's health sciences

    New GLC research building, ETH Zurich: Today's facade technology for tomorrow's health sciences

    With the new building in Gloriarank (GLC), ETH Zurich is creating a modern development and laboratory building at the interface between health sciences and technology in the university district of Zurich Zentrum. Together with partners, ETH Zurich would like to set a milestone in medical technology research and application. Research groups will meet in the new building and work more closely together on research projects with industry, the University of Zurich, the University Hospital Zurich and other university hospitals. ETH Zurich is also making an architectural statement with the new building. The attractive connection of the structure to the existing ETZ building creates a central courtyard, the heart of which is the listed Scherrer lecture hall. The inner courtyard created in this way becomes the center around which the main entrances and public facilities are grouped.

    When it comes to architecture, “Everything is Roger” here.
    He speaks of "Maison de Verre", but in this case he does not mean the famous 1930s glass house in Paris – the Zurich architect Roger Boltshauser. Rather, with the GLC research building, he created a sensational building that, with its glass facade made of glass block elements assembled in a cassette-like manner and the ventilation wings staggered in depth, creates a sublime heaviness that does justice to its representative character. Since the use of glass blocks as a façade material in contemporary industrial and university buildings has a long tradition, the architect redesigned the material for this project in terms of design, technology and energy. It not only meets today's enormously high demands on energy and sustainability. Rather, through the combination of reduction and robustness of the elements used, the design corresponds to the basic urban planning attitude of the quarter.

    Thinking together means thinking ahead.
    3,866 m² of steel facade, 22,550 m² of floor space, 1,875 mm high casement windows with a projection of 2,800 mm, the strictest environmental and fire protection standards and much more: the new GLC building was a challenge in every respect, which was mastered thanks to the open and constructive exchange of ideas between the companies involved was mastered. A good example of this are the particularly heavy cleaning blades. Due to its complex geometry, Aepli Metallbau – in cooperation with Jansen AG – subjected it to an endurance test beforehand. A prototype was specially built for this purpose. Exactly 1250 problem-free openings and closings later, it was clear: everything works perfectly!

    Contact:
    Matthew Elmer
    Aepli Metallbau AG
    Direct phone +41 71 388 82 38
    matthias.elmer@aepli.ch
    www.aepli.ch